As Chancellor Merkel visits US, MSF urges Germany to stop blockade on pandemic ‘TRIPS waiver’ | Médecins Sans Frontières Access Campaign Skip to main content Media room Contact msf.org About us About the Access Campaign Our 2022 wishlist Media room Latest news Jobs Get Involved! Sign up to stay updated and find out how you can get involved. Email Address Data protection consent I want to receive emails from MSF and I have read and agree with the privacy policy. Our work COVID-19 Explainer: A bold proposal at the WTO by India and South Africa Diabetes Drug-resistant infections HIV/AIDS Hepatitis C Hypertension Patents and intellectual property The Patent Oppositions Database Spotlight on: Access to medicines in Europe Spotlight on: TRIPS, TRIPS Plus Research and development Spotlight on: the Big Pharma double-dip Tropical and neglected diseases Spotlight on: Snakebite Tuberculosis Vaccines Explainer: COVID-19 vaccines - Recommendations for equitable access Share the Tech - Save Lives Get Involved! Sign up to stay updated and find out how you can get involved. Email Address Data protection consent I want to receive emails from MSF and I have read and agree with the privacy policy. Get involved Active campaigns No Patents in a Pandemic 20 years of Advocacy in Action Share the Tech - Save Lives Campaign success stories #NoMoreTears Johnson & Johnson Can you hear us? Novartis 'Drop the case' Trans-pacific Partnership (TPP) Take Action Get Involved! Sign up to stay updated and find out how you can get involved. Email Address Data protection consent I want to receive emails from MSF and I have read and agree with the privacy policy. Resources Press releases Statements Letters Opinion articles Feature stories Interviews Blog Newsletters Publications Research articles Topic overview pages Spotlight pages Videos Photo stories Infographics Events Get Involved! Sign up to stay updated and find out how you can get involved. Email Address Data protection consent I want to receive emails from MSF and I have read and agree with the privacy policy. Media room Contact msf.org About us About the Access Campaign Our 2022 wishlist Media room Latest news Jobs Get Involved! Sign up to stay updated and find out how you can get involved. Email Address Data protection consent I want to receive emails from MSF and I have read and agree with the privacy policy. Our work COVID-19 Explainer: A bold proposal at the WTO by India and South Africa Diabetes Drug-resistant infections HIV/AIDS Hepatitis C Hypertension Patents and intellectual property The Patent Oppositions Database Spotlight on: Access to medicines in Europe Spotlight on: TRIPS, TRIPS Plus Research and development Spotlight on: the Big Pharma double-dip Tropical and neglected diseases Spotlight on: Snakebite Tuberculosis Vaccines Explainer: COVID-19 vaccines - Recommendations for equitable access Share the Tech - Save Lives Get Involved! Sign up to stay updated and find out how you can get involved. Email Address Data protection consent I want to receive emails from MSF and I have read and agree with the privacy policy. Get involved Active campaigns No Patents in a Pandemic 20 years of Advocacy in Action Share the Tech - Save Lives Campaign success stories #NoMoreTears Johnson & Johnson Can you hear us? Novartis 'Drop the case' Trans-pacific Partnership (TPP) Take Action Get Involved! Sign up to stay updated and find out how you can get involved. Email Address Data protection consent I want to receive emails from MSF and I have read and agree with the privacy policy. Resources Press releases Statements Letters Opinion articles Feature stories Interviews Blog Newsletters Publications Research articles Topic overview pages Spotlight pages Videos Photo stories Infographics Events Get Involved! Sign up to stay updated and find out how you can get involved. Email Address Data protection consent I want to receive emails from MSF and I have read and agree with the privacy policy. Medicines shouldn’t be a luxury Take action! Get involved Share the Tech If mRNA vaccine technology from Moderna, BioNTech and Pfizer were shared, manufacturers in low- and middle-income countries could produce vaccines for global pandemic preparedness, as well as diseases of concern such as HIV, TB and malaria. Search Sort by DateRelevance toggle menu toggle menu Press release | 14 July 2021 As Chancellor Merkel visits US, MSF urges Germany to stop blockade on pandemic ‘TRIPS waiver’ COVID-19 Berlin/New York, 14 July 2021 — Ahead of German Chancellor Angela Merkel's visit to the United States, Médecins Sans Frontières/Doctors Without Borders (MSF) called on the German Chancellor to stop blocking the landmark “TRIPS waiver” at a time when COVID-19 has already killed more than four million people across the globe and there are huge inequities in access to COVID-19 medical tools. Both the United States and Germany host major pharmaceutical companies producing COVID-19 medical tools, including vaccines, and have also invested substantial sums of money in the creation of these products. "Germany is increasingly isolated with its stance blocking the TRIPS waiver, and is hindering global containment of the pandemic" Barbara Gerold-Wolke Acting General Director MSF Germany More than 100 nations, including the US, have come out in support and welcomed the proposal to waive certain intellectual property (IP) protections on COVID-19 medical tools during the pandemic. However, the European Union, with strong backing from Germany, has refused to engage in productive discussions on the waiver. Although Chancellor Merkel herself recently emphasised that the pandemic will not be defeated until the vaccination rate is high enough worldwide, only 3.2 percent of the total available vaccines have gone to 134 low- and middle-income countries via the COVAX initiative. With new and more transmissible variants spreading in low- and middle-income countries, shortages of diagnostics, treatments, and other lifesaving medical tools continue to add pressure on these countries, with their health systems being pushed to the brink of collapse. “Germany is increasingly isolated with its stance blocking the TRIPS waiver, and is hindering global containment of the pandemic,” said Barbara Gerold-Wolke, acting General Director for MSF in Germany. “Chancellor Merkel should use the meeting with US President Joe Biden as an opportunity to revisit her rigid stance on intellectual property rights and take urgent measures to increase access to COVID-19 medical tools – now is her chance to act as a champion for global health. We’re strongly calling on Chancellor Merkel to support the TRIPS waiver, to immediately transfer vaccine doses to low- and middle-income countries through the COVAX facility, and to push pharmaceutical corporations to transfer technology and know-how to other companies.” If adopted, the TRIPS waiver could provide countries with new options to address the limitations in today’s international intellectual property rules and remove legal uncertainties and barriers that may impede production and supply of all COVID-19 medical tools, including drugs, diagnostics and vaccines. In a groundbreaking move in early May, the US signaled its support for the waiver. On 4 June, the EU published a counter-proposal focusing on ‘compulsory licensing,’ which is an important legal tool but the EU proposal brings nothing significantly new to the table and instead is merely a maneuver to stall the TRIPS waiver negotiation process. "The US decision in May to support a waiver of intellectual property protections for COVID-19 vaccines was a giant step forward, but that effort now appears to have stalled,” said Avril Benoît, Executive Director of MSF- USA. “President Biden should use this summit meeting with Chancellor Merkel to urge Germany to stop blocking the TRIPS waiver. The US should also expand its support for the waiver to apply not only to vaccines, but also to cover treatments, diagnostics, and other essential medical tools for COVID-19. World leaders have repeatedly proclaimed that COVID-19 products should be treated as ‘global public goods’ for the duration of the pandemic, but so far have not delivered on these lofty statements.” Even though more and more countries are backing the TRIPS Waiver, Chancellor Merkel and her government continue to oppose it and have time and again propagated the myth that even in a pandemic there can be no exceptions to IP protection in order to ensure future innovation. “With COVID-19 medicines and vaccines, public sector resources and philanthropic funding have been the main drivers of the unprecedented research efforts to date,” said Yuanqiong Hu, Senior Legal and Policy Advisor at MSF’s Access Campaign. "Handing over monopoly control of these critical COVID-19 medical tools to corporations will do nothing but hamper the scale up of production and diversified supply needed to ensure global equitable access to these products to end the pandemic. To really ensure that these tools are treated as global public goods, the German government and the European Union must support the TRIPS Waiver without wasting any more time.” Read, watch, share Filter by - Any -BlogCampaignEventsExplainerFact sheetFeature storyInfographicInterviewIssue briefLetterNewsletterOpinion articlePhoto storyPress releaseReportReport seriesResearch articleSpeechSpotlightStatementTechnical briefThe issuesTopic overviewVideo Explainer Explainer | 04 April 2022 COVID-19 Neither the waiver people need nor a solution fit for a pandemic Explainer Explainer | 08 September 2021 COVID-19 4 reasons why Pfizer, BioNTech and Moderna must share COVID-19 mRNA vaccine technology NOW! 5 min Photograph by Kristof Vadino Explainer Explainer | 18 June 2021 COVID-19 3 reasons why the EU’s TRIPS Waiver counter-proposal is an insufficient solution in a pandemic 4 min Video Video | 28 July 2022 COVID-19 #ShareTheTech - why pharma must share the mRNA vaccine technology Newsletter Newsletter | 24 July 2022 COVID-19 WTO adopts inadequate text, not a real Waiver on COVID monopolies Photograph by Nicolas Guyonnet Press release Press release | 24 June 2022 COVID-19 MSF responds to BioNTech announcement that it will set up first “BioNTainers” by end of 2022 3 min Press release Press release | 17 June 2022 COVID-19 Inability to agree a real pandemic intellectual property Waiver at WTO is a devastating global failure for people the world over 3 min Letter Letter | 15 June 2022 COVID-19 Open CSO letter to WTO Trade Ministers: Do not accept the current draft, demand a real Waiver 9 min Load More Campaign No Patents, No Monopolies in a Pandemic Monopolies are often an obstacle between people and the lifesaving health tools they need. Patents and other exclusivities limit supply and keep prices high. The COVID-19 pandemic has shown we need new rules that can help every country address the fast-growing medical needs during a major global health crisis. Over 100 countries at the World Trade Organization (WTO) supported a proposal to temporarily waive patents, trade secrets and other intellectual property (IP) on all COVID-19 medical tools. Read more Photo by Tadeu Andre Video | 28 July 2022 #ShareTheTech - why pharma must share the mRNA vaccine technology Press release | 24 June 2022 MSF responds to BioNTech announcement that it will set up first “BioNTainers” by end of 2022 Press release | 17 June 2022 Inability to agree a real pandemic intellectual property Waiver at WTO is a devastating global failure for people the world over Letter | 15 June 2022 Open CSO letter to WTO Trade Ministers: Do not accept the current draft, demand a real Waiver Press release | 15 June 2022 Trade Ministers at WTO should not accept current draft of Ministerial Decision on TRIPS Navigate About the Access Campaign 1999-2019: 20 Years of Advocacy in Action Contact us Get involved Our work Resources Search Get updates Sign up for our newsletter Privacy & data protection information Contact MSF Access Campaign Médecins Sans Frontières Route de Ferney 140 P.O. Box 1224 CH-1211 Geneva 1, Switzerland Phone:+41 22 849 8484 Fax:+41 22 849 8404 E-mail: access(at)msf.org Follow us on Twitter and Facebook Twitter Vimeo Facebook